Thursday, November 16, 2017 2:16:01 PM
"Goldman Sachs Group Inc. lifted its holdings in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 323.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,977 shares of the biotechnology company’s stock after acquiring an additional 48,090 shares during the quarter. Goldman Sachs Group Inc. owned 0.21% of Conatus Pharmaceuticals worth $363,000 as of its most recent SEC filing."
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM